The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72894
Title:
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Authors:
Rosa, Daniela D; Clamp, Andrew R; Mullamitha, Saifee A; Ton, Nhuan C; Lau, Sin C; Byrd, Louise M; Clayton, Richard D; Slade, Richard J; Kitchener, Henry C; Shanks, Jonathan H; Wilson, Gregory; McVey, Rhona J; Hasan, Jurjees; Swindell, Ric; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
BACKGROUND: To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer. METHODS: We stratified patients according to the start of platinum-based chemotherapy in group 1 (within 4 weeks from surgery), group 2 (between 4 and 8 weeks) and group 3 (between 8 and 12 weeks). RESULTS: Three hundred and ninty-four stage III ovarian cancer patients were analysed. In the multivariate analysis there were no differences in survival according to the interval between surgery and chemotherapy among the three groups. The independent prognostic variables were type of procedure (p = 0.014), performance status (p = 0.040) and post-chemotherapy CA-125 (p < 0.0001). CONCLUSIONS: The interval between surgery and chemotherapy does not affect outcome.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester. dornellesrosa@hotmail.com
Citation:
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. 2006, 32 (5):588-91 Eur J Surg Oncol
Journal:
European Journal of Surgical Oncology
Issue Date:
Jun-2006
URI:
http://hdl.handle.net/10541/72894
DOI:
10.1016/j.ejso.2006.02.013
PubMed ID:
16569491
Type:
Article
Language:
en
ISSN:
0748-7983
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRosa, Daniela D-
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorMullamitha, Saifee A-
dc.contributor.authorTon, Nhuan C-
dc.contributor.authorLau, Sin C-
dc.contributor.authorByrd, Louise M-
dc.contributor.authorClayton, Richard D-
dc.contributor.authorSlade, Richard J-
dc.contributor.authorKitchener, Henry C-
dc.contributor.authorShanks, Jonathan H-
dc.contributor.authorWilson, Gregory-
dc.contributor.authorMcVey, Rhona J-
dc.contributor.authorHasan, Jurjees-
dc.contributor.authorSwindell, Ric-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T17:47:26Z-
dc.date.available2009-07-07T17:47:26Z-
dc.date.issued2006-06-
dc.identifier.citationThe interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. 2006, 32 (5):588-91 Eur J Surg Oncolen
dc.identifier.issn0748-7983-
dc.identifier.pmid16569491-
dc.identifier.doi10.1016/j.ejso.2006.02.013-
dc.identifier.urihttp://hdl.handle.net/10541/72894-
dc.description.abstractBACKGROUND: To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer. METHODS: We stratified patients according to the start of platinum-based chemotherapy in group 1 (within 4 weeks from surgery), group 2 (between 4 and 8 weeks) and group 3 (between 8 and 12 weeks). RESULTS: Three hundred and ninty-four stage III ovarian cancer patients were analysed. In the multivariate analysis there were no differences in survival according to the interval between surgery and chemotherapy among the three groups. The independent prognostic variables were type of procedure (p = 0.014), performance status (p = 0.040) and post-chemotherapy CA-125 (p < 0.0001). CONCLUSIONS: The interval between surgery and chemotherapy does not affect outcome.en
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCA-125 Antigen-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshFallopian Tubes-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshHysterectomy-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshNeoplasm, Residual-
dc.subject.meshOmentum-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshOvariectomy-
dc.subject.meshPlatinum Compounds-
dc.subject.meshPrognosis-
dc.subject.meshSurvival Analysis-
dc.subject.meshTime Factors-
dc.subject.meshTreatment Outcome-
dc.titleThe interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester. dornellesrosa@hotmail.comen
dc.identifier.journalEuropean Journal of Surgical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.